Weihrauch T R
Z Gastroenterol. 1983 Mar;21 Suppl:50-2.
At present it has not been sufficiently established by controlled trials that antacids are more efficacious in the treatment of reflux symptoms and reflux esophagitis than placebo. Furthermore, Gaviscon does not seem to offer advantages in comparison to traditional antacids. It is suggested that the value of antacids in the treatment of reflux esophagitis should be further evaluated in controlled studies using higher antacid dosages for more extended periods of time, at least 8 to 12 weeks.
目前，对照试验尚未充分证实抗酸剂在治疗反流症状和反流性食管炎方面比安慰剂更有效。此外，与传统抗酸剂相比，胃仙-U似乎并无优势。建议在对照研究中进一步评估抗酸剂在治疗反流性食管炎方面的价值，使用更高剂量的抗酸剂并延长疗程，至少8至12周。
